Vascular complications and bleeding after balloon aortic valvuloplasty performed with or without heparin: HEPAVALVE randomized study. (April 2022)

• Record Type: Journal Article
• Authors: Akodad, Mariama; Labour, Jessica; Nogue, Erika; Delseny, Delphine; Macia, Jean-Christophe; Gervasoni, Richard; Lattuca, Benoit; Nagot, Nicolas; Roubille, François; Cayla, Guillaume; Leclercq, Florence
• Is Part Of: IJC heart & vasculature. Volume 39(2022)
• Publication Date: 2022-04
• Subjects: Balloon aortic valvuloplasty -- Vascular and bleeding complications -- Aortic stenosis -- Percutaneous interventions; Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Pathophysiology -- Periodicals; 616.1005
• DOI: 10.1016/j.ijcha.2021.100951
• Languages: English
• ISSNs: 2352-9067

Abstract

Highlights: Vascular and bleeding events remain frequent after balloon aortic valvuloplasty. Balloon aortic valvuloplasty without per procedural heparin is associated with a reduction of major VC and bleeding events. Balloon aortic valvuloplasty without per procedural heparin is not associated with an increased risk of ischemic complications. Abstract: Background: Vascular and bleeding events remain the main complications after balloon aortic valvuloplasty (BAV). While BAV is usually performed with per procedural heparin injection, BAV performed without heparin may reduce hemorrhagic events. We aimed to determine whether vascular and bleeding complications may be reduced with BAV performed without heparin. Methods: This randomized, double-blind, placebo-controlled study was conducted from January 2013 to September 2016. Patients were randomly assigned to placebo or intravenous unfractionated heparin (UH) 50 IU/kg bolus during the procedure. The primary endpoint included major vascular, bleeding and ischemic complications (stroke, transient ischemic attack, myocardial infarction) according to VARC-2 criteria. Results: Among 89 randomized patients, 82 completed the study (n = 39 in the UH group and n = 43 in the placebo group). At baseline, diabetes, sex male and renal failure were more frequent in the UH group and peripheral artery disease was more frequent in the placebo group. The primary endpoint was achieved in 7 patients (8.5%), 1 in the placebo group (2.3%) versus 6 in the UH group (15.4%). After adjustment on diabetes, sex, renal failure, peripheral artery disease, percutaneous closure device and chronic obstructive pulmonary disease, UH utilization was associated with a significant risk of major vascular, bleeding and ischemic complications (primary endpoint) (adj OR: 11.9; 95%CI: 1.2–117.2; p = 0.03). Hospitalization length was lower in the placebo group compared to the UH group (p = 0.03). Conclusions: BAV without per procedural UH was associated with a reduction of major VC and bleeding events without increasing the ischemic risk and with a shorter hospitalization length.